Skindex-29
Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes.
Kilderegister
Siteringer kopiert ordrett fra metodens kilderegister. Ingen påstandsnivåverifisering er underforstått fra dem.
- Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713. · DOI 10.1111/1523-1747.ep12365600
- Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433-1440. · DOI 10.1001/archderm.133.11.1433
Kuraterte påstander
Påstander lagret i bevishovedboken, hver med sin egen vurdering.
Denne visningen finner ikke opp en påstandsvurdering når hovedboken ikke har noen.
Relaterte metoder
Generert fra metodegrafen og vist som maskinforslåtte relasjoner – ingen bevispåstand er underforstått.